Clinical Trial UCI-17-90


A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy

Principal Investigator

Sai-Hong Ignatius Ou


Learn More

For more information about cancer clinical trials at the Chao Family Comprehensive Cancer Center, please call toll-free: 877.UC.STUDY (877.827.8839) or email